The ABCD1 Knockout HEK293T Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HEK293T human embryonic kidney cell line, designed as a loss-of-function model for the peroxisomal transporter ABCD1. This product comprises a heterogeneous mixture of edited cells, each carrying targeted disruptions in the ABCD1 gene, enabling population-level studies of gene function without the need for clonal selection. The polyclonal format preserves the genetic diversity inherent in the knockout pool, allowing researchers to assess the collective impact of ABCD1 inactivation on peroxisomal fatty acid metabolism and related cellular processes. This model is particularly suited for applications requiring robust, batch-consistent material for high-throughput screening or biochemical assays, where a monoclonal line might introduce clone-specific biases.
HEK293T cells are human embryonic kidney epithelial cells transformed with adenovirus type 5 DNA and stably express the SV40 large T antigen, which promotes episomal replication of plasmids containing the SV40 origin of replication. These features confer exceptionally high transfection efficiency and robust protein expression capacity, making HEK293T the preferred host for recombinant protein production and lentiviral packaging in both academic and industrial settings. The epithelial origin provides a context rich in membrane trafficking and organelle biogenesis pathways, including a functional peroxisomal compartment, making this line an appropriate platform for investigating peroxisome-associated genes such as ABCD1. The well-characterized genomic landscape and ease of genetic manipulation further enhance its utility for generating targeted gene disruptions via CRISPR/Cas9.
ABCD1 encodes the peroxisomal ATP-binding cassette transporter ALDP, which is anchored in the peroxisomal membrane and facilitates the import of very-long-chain fatty acids (VLCFAs) as their CoA esters into the peroxisomal lumen. This transport step is essential for the subsequent beta-oxidation of VLCFAs, a process requiring the sequential action of enzymes including ACOX1, D-bifunctional protein (DBP), and sterol carrier protein X (SCPx). The expression of ABCD1 is transcriptionally regulated by peroxisome proliferator-activated receptor alpha (PPAR??) agonists such as fibrates, which promote peroxisome biogenesis and fatty acid catabolism. ALDP functionally interacts with the peroxisomal biogenesis factors PEX19 and PEX3 for proper targeting to the peroxisomal membrane, and it shares partial functional redundancy with its homolog ABCD2. Disruption of ABCD1 leads to reduced peroxisomal VLCFA import, impairing beta-oxidation and causing the accumulation of VLCFAs, notably C24:0 and C26:0, within the cytosol.
In the HEK293T background, the knockout of ABCD1 generates a cell-autonomous model of impaired VLCFA metabolism that recapitulates key biochemical hallmarks of X-linked adrenoleukodystrophy (X-ALD). While HEK293T cells are not of neural origin, they provide a tractable system to dissect the molecular consequences of ALDP deficiency, including alterations in peroxisomal enzyme activity, reactive oxygen species generation, and lipid membrane composition. The high transfection efficiency of HEK293T cells permits complementation studies with wild-type or mutant ABCD1 constructs, enabling structure-function analyses and the validation of disease-associated mutations. Moreover, the rapid growth and ease of culture make polyclonal knockout pools cost-effective for scaling up experiments such as drug screening campaigns aimed at reducing VLCFA levels.
This polyclonal knockout model supports a wide range of research applications centered on peroxisomal disorders and lipid metabolism. It is ideally suited for VLCFA quantification by gas chromatography-mass spectrometry (GC-MS) to assess metabolic outcomes of ABCD1 disruption, as well as for characterizing ABCD1 protein expression by western blotting and peroxisomal localization by immunofluorescence. Functional assays including peroxisomal fatty acid oxidation measurements and cell viability tests under VLCFA-induced lipotoxicity can be employed to evaluate therapeutic interventions. The model also serves as a tool for studying peroxisome biogenesis and the interplay between ABCD1 and interacting partners such as ABCD2 and PEX19. For further information, contact Ascent Research.
